Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences

Antibody-drug conjugates (ADCs) are a recent, revolutionary approach for malignancies treatment, designed to provide superior efficacy and specific targeting of tumor cells, compared to systemic cytotoxic chemotherapy. Their structure combines highly potent anti-cancer drugs (payloads or warheads) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Barreca, Marilia, Lang, Noémie, Tarantelli, Chiara, Spriano, Filippo, Barraja, Paola, Bertoni, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Exploration 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834635/
https://www.ncbi.nlm.nih.gov/pubmed/36654819
http://dx.doi.org/10.37349/etat.2022.00112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834635/
https://www.ncbi.nlm.nih.gov/pubmed/36654819
http://dx.doi.org/10.37349/etat.2022.00112

Ejemplares similares